Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Rosu

227 clinical trials in Rosu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Rosu at a glance
227
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

227 trials in Rosu

Open in trial search

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Obesity+1

Recruiting

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Rosu

What the registry says about research in the country

01 Cardiovascular Disease – Atrial Fibrillation

Research in Rosu is centered on a common heart rhythm disorder that raises the chance of serious vascular events.

  • Evaluation of REGN7508 compared with standard anticoagulant therapy
  • Combined REGN7508 and REGN9933 versus placebo
  • Risk assessment of clinically relevant bleeding
  • Stroke and systemic embolism prevention for patients unsuitable for oral anticoagulation

The trials aim to expand treatment choices and lower the incidence of stroke and embolic complications in atrial fibrillation.

02 Anticoagulation Safety in Atrial Fibrillation

Ongoing studies examine how to protect patients from ischemic stroke while reducing the likelihood of major bleeding events.

  • Comparison of bleeding risk between experimental agents and apixaban
  • Evaluation of major bleeding outcomes with dual‑target therapy
  • Analysis of stroke prevention effectiveness in high‑risk cohorts
  • Safety profiling for participants unable to use conventional oral anticoagulants

Findings are expected to inform safer anticoagulation strategies for individuals living with atrial fibrillation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.